Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15715802 | 0.88 | CD274 (0.43) | CD274BCHECNR2ADRB2HTR1A | |
| SCHEMBL15258425 | 0.87 | CD274 (0.44) | CD274BCHECNR2ADRB2HTR1A | |
| SCHEMBL16342025 | 0.87 | CD274 (0.47) | CD274BCHECNR2ADRB2HTR1A | |
| SCHEMBL12222536 | 0.86 | CD274 (0.44) | CD274BCHECNR2ADRB2HTR1A | |
| SCHEMBL14511687 | 0.78 | ADRB2 (0.40) | CD274BCHECNR2ADRB2HTR1A | |
| SCHEMBL13857331 | 0.74 | TAS1R3 (0.45) | CD274BCHECNR2ADRB2HTR1A | |
| SCHEMBL13912242 | 0.72 | TDP1 (0.44) | BCHECNR2ADRB2HTR1ACA12 | |
| SCHEMBL12706029 | 0.72 | TP53 (0.42) | BCHECNR2ADRB2HTR1ACA12 | |
| SCHEMBL15987190 | 0.71 | TDP1 (0.46) | BCHECNR2ADRB2HTR1ACA12 | |
| SCHEMBL12515101 | 0.69 | BCHE (0.49) | BCHECNR2ADRB2HTR1ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032408-A1 | Novel spacer moiety for poly (ethylene glycol) modified peptide based compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032408-A1 | Novel spacer moiety for poly (ethylene glycol) modified peptide based compounds | NGLY1, YWHAZ, PAM | CD274 3285/4885BCHE 401/4885CNR2 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.